TCRX

Company Overview — What Does TScan Therapeutics, Inc. Do?

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. TScan Therapeutics, Inc. (TCRX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David P. Southwell and employs approximately 100 people. With a market capitalization of $59M, TCRX is one of the notable companies in the Healthcare sector.

TScan Therapeutics, Inc. (TCRX) Stock Rating — Avoid (April 2026)

As of April 2026, TScan Therapeutics, Inc. receives a Avoid rating with a composite score of 23.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TCRX ranks #4,091 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TScan Therapeutics, Inc. ranks #719 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TCRX Stock Price and 52-Week Range

TScan Therapeutics, Inc. (TCRX) currently trades at $1.03. The stock lost $0.03 (2.8%) in the most recent trading session. The 52-week high for TCRX is $2.57, which means the stock is currently trading -59.9% from its annual peak. The 52-week low is $0.88, putting the stock 16.7% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is TCRX Overvalued or Undervalued? — Valuation Analysis

TScan Therapeutics, Inc. (TCRX) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.49x, versus the sector average of 2.75x. The price-to-sales ratio is 6.91x, compared to 1.66x for the average Healthcare stock.

At current multiples, TScan Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

TScan Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

TScan Therapeutics, Inc. (TCRX) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -111.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.7% versus the sector average of -33.1%.

On a margin basis, TScan Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1877.9% (sector: -66.1%). Net profit margin stands at -1761.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 368.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TCRX Debt, Balance Sheet, and Financial Health

TScan Therapeutics, Inc. has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.41x, indicating strong short-term liquidity. Total debt on the balance sheet is $33M. Cash and equivalents stand at $170M.

TCRX has a beta of 1.30, meaning it is more volatile than the broader market — a $10,000 investment in TCRX would be expected to move 29.9% more than the S&P 500 on any given day. The stability factor score for TScan Therapeutics, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

TScan Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, TScan Therapeutics, Inc. reported revenue of $9M and earnings per share (EPS) of $-1.00. Net income for the quarter was $-137M. Gross margin was 100.0%. Operating income came in at $-145M.

In FY 2025, TScan Therapeutics, Inc. reported revenue of $10M and earnings per share (EPS) of $-1.00. Net income for the quarter was $-130M. Revenue grew 266.7% year-over-year compared to FY 2024. Operating income came in at $-136M.

In Q3 2025, TScan Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-36M. Revenue grew 139.4% year-over-year compared to Q3 2024. Operating income came in at $-37M.

In Q2 2025, TScan Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-37M. Revenue grew 473.9% year-over-year compared to Q2 2024. Operating income came in at $-39M.

Over the past 8 quarters, TScan Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $536,000 to $9M. Investors analyzing TCRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TCRX Dividend Yield and Income Analysis

TScan Therapeutics, Inc. (TCRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TCRX Momentum and Technical Analysis Profile

TScan Therapeutics, Inc. (TCRX) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

TCRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, TScan Therapeutics, Inc. (TCRX) ranks #719 out of 838 stocks based on the Blank Capital composite score. This places TCRX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TCRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TCRX vs S&P 500 (SPY) comparison to assess how TScan Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TCRX Next Earnings Date

No upcoming earnings date has been announced for TScan Therapeutics, Inc. (TCRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TCRX? — Investment Thesis Summary

The quantitative profile for TScan Therapeutics, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 23/100, a headwind for near-term performance. High volatility (stability score 29/100) increases portfolio risk.

In summary, TScan Therapeutics, Inc. (TCRX) earns a Avoid rating with a composite score of 23.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TCRX stock.

Related Resources for TCRX Investors

Explore more research and tools: TCRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TCRX head-to-head with peers: TCRX vs AZN, TCRX vs SLGL, TCRX vs VMD.